CAMPANI, CLAUDIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.315
AS - Asia 3.041
EU - Europa 2.579
SA - Sud America 381
AF - Africa 89
OC - Oceania 41
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.447
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.254
RU - Federazione Russa 1.031
CN - Cina 993
SG - Singapore 841
IT - Italia 754
HK - Hong Kong 317
KR - Corea 310
BR - Brasile 295
VN - Vietnam 226
IE - Irlanda 149
FR - Francia 119
FI - Finlandia 96
SE - Svezia 93
DE - Germania 87
GB - Regno Unito 79
IN - India 78
PL - Polonia 67
BD - Bangladesh 62
JO - Giordania 48
ID - Indonesia 47
NL - Olanda 43
AU - Australia 41
CA - Canada 39
AR - Argentina 33
IQ - Iraq 19
JP - Giappone 16
ZA - Sudafrica 15
EC - Ecuador 13
NG - Nigeria 13
RO - Romania 13
TR - Turchia 13
UZ - Uzbekistan 13
CI - Costa d'Avorio 10
CO - Colombia 10
ES - Italia 10
PK - Pakistan 10
UA - Ucraina 10
EG - Egitto 9
MX - Messico 9
PE - Perù 8
NP - Nepal 7
PY - Paraguay 7
BJ - Benin 6
CL - Cile 6
DZ - Algeria 6
KE - Kenya 6
MA - Marocco 6
VE - Venezuela 6
AT - Austria 5
PH - Filippine 5
TN - Tunisia 5
IL - Israele 4
OM - Oman 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
CH - Svizzera 3
SA - Arabia Saudita 3
TH - Thailandia 3
AM - Armenia 2
AZ - Azerbaigian 2
BE - Belgio 2
BG - Bulgaria 2
BY - Bielorussia 2
CG - Congo 2
CY - Cipro 2
HN - Honduras 2
JM - Giamaica 2
KG - Kirghizistan 2
MY - Malesia 2
RS - Serbia 2
SI - Slovenia 2
SN - Senegal 2
UY - Uruguay 2
AL - Albania 1
BB - Barbados 1
BO - Bolivia 1
BS - Bahamas 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GE - Georgia 1
GN - Guinea 1
GR - Grecia 1
GT - Guatemala 1
HU - Ungheria 1
LB - Libano 1
LT - Lituania 1
LV - Lettonia 1
MD - Moldavia 1
MG - Madagascar 1
MM - Myanmar 1
MT - Malta 1
MU - Mauritius 1
MZ - Mozambico 1
NA - Namibia 1
NI - Nicaragua 1
NO - Norvegia 1
PA - Panama 1
PS - Palestinian Territory 1
Totale 9.439
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.037
Singapore 667
Ashburn 590
Hefei 402
Seoul 308
Hong Kong 276
San Jose 162
Dublin 149
Milan 120
Beijing 109
Florence 102
Los Angeles 98
Ho Chi Minh City 94
Chandler 71
Moscow 70
Council Bluffs 69
Fairfield 69
Warsaw 63
Buffalo 61
Kent 60
Rome 59
Helsinki 56
Lauterbourg 51
Hanoi 50
New York 46
Altamura 42
Lawrence 41
Munich 41
The Dalles 39
Shanghai 38
London 37
Melbourne 37
Jakarta 36
Houston 33
Paris 30
Cambridge 28
São Paulo 28
Bengaluru 25
Dallas 24
Woodbridge 24
Arezzo 23
Bologna 23
Lappeenranta 23
Princeton 22
Wilmington 22
Mumbai 21
Boston 19
Naples 19
Seattle 19
Frankfurt am Main 17
Turku 16
Boardman 14
Tokyo 14
West Jordan 14
Abuja 13
Amman 13
Turin 12
Genoa 11
Haiphong 11
Abidjan 10
Chicago 10
City of London 10
Orem 10
Rio de Janeiro 10
San Diego 10
Toronto 10
Ann Arbor 9
Atlanta 9
Chennai 9
Montreal 9
Tashkent 9
Timisoara 9
Brooklyn 8
Da Nang 8
Hangzhou 8
Porto Alegre 8
Buenos Aires 7
Guangzhou 7
Medford 7
Miano 7
Modena 7
Nuremberg 7
Parma 7
Piscataway 7
Redondo Beach 7
Washington 7
Amsterdam 6
Belo Horizonte 6
Cotonou 6
Istanbul 6
Johannesburg 6
Newark 6
Prato 6
Riverside 6
San Francisco 6
Bari 5
Biên Hòa 5
Caxias do Sul 5
Curitiba 5
Palermo 5
Totale 5.973
Salva come PNG Salva come JPEG
Nome #
Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis 239
Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study 226
A large rheumatoid nodule mimicking hepatic malignancy 222
Understanding fatigue in primary biliary cholangitis: From pathophysiology to treatment perspectives 211
Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives 205
Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model 203
Circulating biomarkers of response to systemic treatments in advanced hepatocellular 197
Pregnancy outcomes in inflammatory bowel disease: Data from a large cohort survey 195
Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma 191
Practical insights into chronic management of hepatic Wilson's disease 190
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 189
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 188
Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center 185
Extracellular signal-regulated kinase 5 regulates the malignant phenotype of cholangiocarcinoma cells 185
Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma 181
CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib 179
Metabolic disorders across hepatocellular carcinoma in Italy 172
Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma 171
End-procedural adherence to recommended hemodynamic targets does not improve the outcome of elective tips in cirrhotic patients 162
Transjugular intrahepatic Porto-systemic shunt positively influences the composition and metabolic functions of the gut microbiota in cirrhotic patients 157
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study 155
The changing scenario of hepatocellular carcinoma in Italy: an update 155
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 154
Main factors influencing long-term outcomes of liver transplantation in 2022 152
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 151
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study 150
Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: a long-term follow-up study 148
The protease-inhibitor SerpinB3 as a critical modulator of the stem-like subset in human cholangiocarcinoma 147
Pattern of macrovascular invasion in hepatocellular carcinoma 147
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 146
An atypical case of palmo-plantar erythrodysesthesia related to cabozantinib 145
Needs evaluation questionnaire for liver disease: a novel assessment of unmet needs in patients with chronic liver disease 145
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib 143
Characteristics and outcome of anti‐hepatitis D virus positive patients with hepatocellular carcinoma 140
Fragility index of positive phase II and III randomized clinical trials of treatments for hepatocellular carcinoma (2002-2022) 140
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison 140
Prevalence of nutritional risk and malnutrition during and after hospitalization for COVID-19 infection: Preliminary results of a single-centre experience 135
Ganglioside GD2 Contributes to a Stem-Like Phenotype in Intrahepatic Cholangiocarcinoma 134
Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab 134
Time-varying mHAP III is the most accurate predictor of survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization 133
Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC 132
Quick and easy assessment of sarcopenia in cirrhosis: Can ultrasound be the solution? 132
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib 127
Elusive Hepatic Nodules 126
No correlation between MASLD and poor outcome of Atezolizumab‐Bevacizumab therapy in patients with advanced HCC 125
Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs 125
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 124
Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab 120
Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab 119
Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA 118
Statin-induced, immune-mediated injury with simultaneous targeting of skeletal muscle, skin and liver 118
Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes 117
Systemic treatment of hepatocellular carcinoma: the times they are a-changin' 116
The upward trajectory of the UEG journal: Next Generation Trainee Editors 116
Biological therapies in patients with liver disease: are they really lifesavers? 113
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 105
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 102
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment 97
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma 97
Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice 95
Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care 91
Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors 87
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 80
Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab 60
Predictors of non‐transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection 50
Probiotics and the gut-liver axis 46
Minimally invasive hepatectomy vs. thermoablation for single small (≤3 cm) hepatocellular carcinoma: A weighted real-life national comparison 26
Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab 15
Survival in patients receiving reduced dose intensity of bevacizumab for unresectable hepatocellular carcinoma 10
Liver Decompensation in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Real-life Study 9
Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma 5
Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab 5
Correction to: CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib 5
The Effect of Metformin on Atezolizumab/Bevacizumab Treatment in Patients with Hepatocellular Carcinoma and Diabetes 4
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab 4
Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab 3
Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data 2
null 2
Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma 1
Totale 9.571
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.126
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.126
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022194 15 1 7 2 2 13 0 10 31 34 32 47
2022/2023586 36 111 31 8 27 109 83 43 70 31 28 9
2023/2024669 23 39 56 18 35 71 42 198 26 71 58 32
2024/20253.230 98 310 178 447 851 458 95 131 144 93 162 263
2025/20264.634 533 704 692 415 368 158 476 187 253 255 190 403
2026/202717 17 0 0 0 0 0 0 0 0 0 0 0
Totale 9.571